ERBB2 and gastric cancer: In summary, with the emergence of novel targets such as CLDN18.1 and FGFR2b as well as improved HER2 and immune checkpoint targeting antibodies, the major challenge will be to optimize the molecular stratification of GC and to identify synergistic combinations of targeted agents.